


DEC. 16. 2004 4:43PM

BMS PATENT DEPT

NO. 2918 P 1  
**RECEIVED**  
CENTRAL FAX CENTER

DEC 16 2004



Bristol-Myers Squibb Company  
Patent Legal Department  
Princeton, NJ 08543-4000

**FACSIMILE TRANSMISSION SHEET**

IN RE APPLICATION OF

ATWAL ET AL.

APPLICATION NO: 10/660,878

FILED: SEPTEMBER 12, 2003

FOR: HETEROCYCLIC DIHYDROPYRIMIDINE COMPOUNDS

**DATE OF TRANSMISSION:** December 16, 2004

**TO:** Examiner Deepak Rao  
Art Unit 1624

**PTO FACSMILE NO:** 571-273-8300

**NUMBER OF PAGES:** (6, including cover sheet)  
INFORMATION DISCLOSURE  
STATEMENT

**FROM:** Bristol-Myers Squibb Company  
ATTN: Deanna L. Baxam

**RETURN FACSIMILE NO.:** (609) 252-4526

This communication is being filed in the United States Patent and Trademark Office by facsimile transmission according to the provisions of 37 C.F.R. § 1.6(d). The sender acknowledges that the receipt date accorded to the correspondence will be the date on which the complete transmission is received in the Patent and Trademark Office. As required, the application number of the patent or application is entered as a part of the sender's identification above.

If all pages of this transmission are not received, please immediately contact:

Tina Markee @ (609) 252-4300; or  
Deanna L. Baxam @ (609) 252-4014.

*Incomplete  
page 6 incomplete*

DEC 16 2004 4:44PM

SMS PATENT DEPT

**RECEIVED  
CENTRAL FAX CENTER**

10/29/04 P 2

DEC 16 2004

CASE HA0726DIV

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below by facsimile transmission to the Official PTO Fax Number, (571) 273-8300.

Deanna Baxam  
Type or print name

  
Signature

12/16/04  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LLOYD ET AL.

APPLICATION NO: 10/660,878

FILED: SEPTEMBER 12, 2003

FOR: HETEROCYCLO DIHYDROPYRIMIDINE COMPOUNDS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

The Commissioner is authorized to charge any fee deemed necessary, or credit any overpayment thereof, to the assignee's Deposit Account Number 19-3880.

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4014

Date: December 16, 2004

Respectfully submitted,



Deanna L. Baxam  
Attorney for Applicants  
Reg. No. 45,266

2004 4:44 PM PATENT MS PATENT OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

S.N. 10,10,29,78  
Atty Doctat No. HA 726 DIV

Group 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Cochran et al., "Regionally selective alterations in local cerebral glucose utilization evoked by charybdotoxin, a blocker of central voltage-activated K <sup>+</sup> -channels," Eur J Neurosci. 2001 Nov;14(9):1455-63;
AS	Coleman et al., "Subunit composition of Kv1 channels in human CNS," J Neurochem. 1999 Aug;73(2):849-58;
AT	Davies et al., "Kv channel subunit expression in rat pulmonary arteries," Lung. 2001;179(3):147-61. Epub 2002 Feb 04;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DEC 16, 2004 2:42 PM PATENT & TRADE OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

S.N. 10,291,878  
Att. Docket No. HA726DIV  
Group 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Frey et al., "Blocking of cloned and native delayed rectifier K channels from visceral smooth muscles by phencyclidine," Neurogastroenterol Motil. 2000 Dec;12(6):509-16;
AB	Hanson et al., "UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation." British Journal of Pharmacology.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**